Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Francis on the Benefits of Ovarian Suppression for Younger Women

December 11th 2014

Nab-Paclitaxel Wins Neoadjuvant Taxane Battle in Breast Cancer Trial

December 11th 2014

Nab-paclitaxel (Abraxane) proved markedly more effective than conventional paclitaxel as part of a neoadjuvant regimen for patients with high-risk early breast cancer in a large German study presented at the 2014 San Antonio Breast Cancer Symposium.

Dr. Weigert on Cancer Screening for Women With Dense Breasts

December 10th 2014

Dr. Edith Perez on Immune Checkpoint Inhibition in TNBC

December 10th 2014

Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the potential for immune checkpoint blockage as treatment for patients with advanced breast cancer.

Pembrolizumab Elicits Antitumor Responses in TNBC

December 10th 2014

The PD-1 inhibitor pembrolizumab has demonstrated promising clinical activity with an acceptable safety profile in heavily pretreated patients with recurrent metastatic triple-negative breast cancer.

Early Data Find the PI3K Inhibitor Pictilisib Benefits a Subset of Patients With MBC

December 10th 2014

The addition of the investigational PI3K inhibitor pictilisib to fulvestrant in patients with metastatic breast cancer yielded some intriguing findings in the phase II FERGI study.

Chemo Alone May Be Optimal in HER2-Positive Patients With High TIL Levels

December 10th 2014

Among HER2-positive breast cancer patients treated with chemotherapy alone, women with high levels of stromal tumor-infiltrating lymphocytes had an 80% lower likelihood of disease recurrence compared to those with lower TIL counts.

Analyzing CTCs Using Next-Generation Sequencing

December 5th 2014

Next-Generation of CTC Technology

December 5th 2014

Clinical Utility of Circulating Tumor Cells

December 5th 2014

Latest News & Insight: December 5, 2014

December 5th 2014

Joan Lunden to Keynote 32nd Annual Miami Breast Cancer Conference

December 5th 2014

Physicians' Education Resource®, LLC (PER®), to Sponsor Innovative CME Conference for Breast Cancer Specialists

Dr. Carey Discusses Treatment Challenges in TNBC

December 4th 2014

Lisa A. Carey, MD, the Division Chief of Hematology and Oncology at the University of North Carolina and the Physician-in-Chief at North Carolina Cancer Hospital, discusses triple-negative breast cancer (TNBC) and the importance of understanding how it differs from other types of breast cancer.

From Bedside to Bench

November 29th 2014

Based on a current laboratory research project, Zarah Dulce F. Lucas, MD, discusses microRNAs and their potential to predict brain metastases in patients with triple-negative and HER2-positive breast cancer.

PARP Inhibitors for Breast and Ovarian Cancers

November 26th 2014

PARP inhibitors represent an exciting new class of anticancer agents and are currently being evaluating in phase III for a number of different indications.

Pre-Chemo Abiraterone Extends Survival in CRPC

November 21st 2014

ADT With GnRH Antagonists in Prostate Cancer

November 21st 2014

Upcoming Advances for GU Cancers

November 21st 2014

Latest News & Insight: November 20, 2014

November 21st 2014

Updated Data Continues to Support Adjuvant Trastuzumab

November 20th 2014

Adding 1-year of adjuvant trastuzumab to chemotherapy continues to demonstrate an improvement in overall survival (OS) and disease-free survival (DFS) for patients with early-stage HER2-positive breast cancer